Modality
ASO
MOA
FXIai
Target
PLK4
Pathway
Notch
Ovarian CaBladder Ca
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Feb 2030
NDA/BLACurrent
NCT06545091
322 pts·Ovarian Ca
2022-03→2030-02·Completed
322 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-183.9y awayPh3 Readout· Ovarian Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2030-02-18 · 3.9y away
Ovarian Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06545091 | NDA/BLA | Ovarian Ca | Completed | 322 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 |